NL-OMON45904已完成不适用
A Phase Ib Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16*-18F-fluoro-17*-estradiol Positron Emission Tomography Imaging - RAD1901
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patients with histologically-proven, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, inoperative, and/or mBC.;a) ER-positive tumour defined as * 1% staining by IHC as defined in the 2010 ASCO recommendations for ER testing.;b) HER2-negative tumour defined as an IHC result of 0 or 1+ for cellular membrane protein expression, or fluorescence in situ hybridisation (ISH) negative result as defined in the 2013 ASCO recommendations for HER2 testing.;2. Tumour progression after * 6 months of at least 1 line of hormonal systemic treatment (SERM, SERD, or aromatase inhibitor) in the metastatic setting;3. Measurable disease according to RECIST criteria v1.1 or clinically evaluable disease. At least 1 non-irradiated lesion (measurable and/or non-measurable) that can be accurately assessed by CT/magnetic resonance imaging/plain X-ray at baseline and follow-up visits;4. Greater than or equal to 18 years of age;5. Patients must be post-menopausal defined as follows:;a) Greater than 56 years of age with amenorrhea for > 12 months;b) Less than 56 years of age with amenorrhea for > 12 months, serum estradiol levels < 20 pg/mL, and follicle stimulating hormone levels > 40 mIU/mL;c) Prior bilateral ovariectomy;d) Pre-menopausal patients who are medically induced to become post-menopausal for purposes of receiving endocrine therapy as standard of care treatment are eligible with documentation of appropriate lab testing;6. No prior treatment with RAD1901, GDC-0810, AZD9496, or other investigational SERD.;7. Eastern Cooperative Oncology Group performance status 0-2;8. Life expectancy > 3 months;9. Resolution of all toxic effects of prior therapy or surgical procedures to Grade * 1 (except alopecia);10. Adequate organ function as defined below:;a) Adequate bone marrow function;* absolute neutrophil count * 1.5 x 109/L;* platelets * 75 x 109/L;b) Adequate hepatic function;* Total bilirubin * 1.5 x upper limit of normal (ULN) regardless of liver metastases. Inclusion of patients with increased serum indirect bilirubin (* 3 x ULN) due to Gilbert*s syndrome is permitted;* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) * 3 x ULN, or AST and ALT * 5 x ULN, if liver metastases are present;* International Normalised Ratio (INR) < 1.6 x ULN;c) Adequate renal function;* Creatinine * 1.5 x ULN for institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 calculated by the Cockcroft-Gault formula for patients with creatinine levels above institutional normal;11. Written informed consent must be given according to International Conference on Harmonisation, Good Clinical Practice, and national regulations;12. Able to comply with protocol
排除标准
- •1. Pregnant or lactating women;2. Severe concurrent disease, infection, or co-morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment;3. Greater than 3 lines of endocrine therapy for metastatic disease;4. Prior anti-cancer treatment or investigational drug therapy within the following windows:;a) Tamoxifen or fulvestrant therapy < 42 days before 1st 18FES-PET scan;b) Any other anti-cancer endocrine therapy < 14 days before 1st dose of study drug;c) Any chemotherapy < 28 days before 1st dose of study drug;d) Any investigational drug therapy < 28 days or 3 half-lives (whichever is longer) prior to the 1st dose of study drug;5. Patient with metastatic disease involving only the liver.;6. Patients with untreated or symptomatic central nervous system metastases. Note: For patients with CNS metastases to be eligible, they must have completed radiotherapy at least 14 days prior to enrollment and require no steroid medication. If anticonvulsant medication is required, patients must be stable on a non-enzyme-inducing anticonvulsant regimen.;7. Patients with known endometrial disorders, including evidence of endometrial hyperplasia, dysfunctional uterine bleeding, or cysts;8. Diagnosis of any secondary malignancy within 6 months prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ;9. Any of the following within 6 months prior to enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias Grade > 2, uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic cardiac failure, or cerebrovascular accident, including transient ischemic attack;10. Patients with a history of any of the following blood disorders:;a) Patients being treated with anticoagulant, e.g, warfarin or heparin, will be allowed to participate provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 1 month prior to the 1st dose of study drug.;b) Any history of coagulopathy, including history of deep vein thrombosis or pulmonary embolus within the past 6 months (except for adequately treated catheter-related venous thrombosis occurring > 1 month prior to the 1st dose of study drug);11. Known human immunodeficiency virus infection, or active hepatitis C or hepatitis B virus infection;12. Patient has impairment of gastrointestinal function or disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, chronic or uncontrolled diarrhoea, malabsorption syndrome, gastric bypass, or small bowel resection);13. Major surgery within 28 days prior to the 1st dose of study drug;14. Local radiation therapy within 7 days prior to 1st dose of study drug;15. Use of strong cytochrome P450 (CYP)3A4/5 inhibitors and strong CYP3A4/5 inducers that cannot be discontinued 7 days prior to the start and for the duration of study treatment;16. Patients with an endometrial thickness > 11 mm
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the biological effects of RAD001 on invasive breast cancerBreast CancerEUCTR2004-001712-31-GBothian Health - University Hospitals Division
进行中（未招募）
不适用
Phase II Study of Single Agent RAD001 in Patients with Colon Cancer and Activating Mutations in the PI3KCA gene.Colon CancerEUCTR2005-005738-11-ESnidad integral de investigación en oncologia37
进行中（未招募）
不适用
A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), evacizumab, fluoropyrimidine, oxaliplatin, and irinotecan-based regimens - NDmetastatic colorectal adenocarcinomaMedDRA version: 9.1Level: LLTClassification code 10051925Term: Intestinal adenocarcinomaEUCTR2006-003255-20-ITOVARTIS FARMA110
进行中（未招募）
不适用
Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer - NDEUCTR2008-006841-25-ITOncology Institute of Southern Switzerland78
进行中（未招募）
不适用
A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - NDPancreatic neuroendocrine tumor (NET)MedDRA version: 6.1Level: PTClassification code 10052399EUCTR2006-006819-75-ITOVARTIS FARMA392